Aviado · Research
Longevity Daily
Wednesday, November 11, 2026
Listen
Today's Brief
The longevity consensus takes a hit today as a decade-long analysis of 11,000 humans finds no survival benefit from rapamycin — and Peter Attia and Andrew Huberman have both reportedly stopped taking it. German scientists have gradually reversed human cells' biological age by decades, and the NYT reports that speech patterns can flag cognitive decline years before symptoms emerge. A third-party audit revealing that 64% of NMN supplements contain almost no actual NMN is essential reading for anyone on a NAD+ stack. A Nature Medicine RCT rounds things out with a clear directive: if you're on tirzepatide, add resistance training or lose muscle.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
How the Way You Speak Today Could Predict Dementia Years Before Diagnosis
Researchers are finding that subtle shifts in speech — pauses, word-finding hesitations, changes in fluency and rhythm — can be detected years before formal cognitive decline sets in. The NYT covers a growing body of evidence pointing to voice as a surprisingly sensitive biomarker for neurodegeneration, potentially enabling earlier intervention than current blood or brain-imaging tests. If voice-based screening tools reach clinical practice, annual speech assessments could eventually become as routine as checking blood pressure.
Read more →GLP-1 Weight Loss Drugs May Also Protect Your Brain — but the Evidence Is Still Evolving
Large patient datasets show that GLP-1 receptor agonists like semaglutide are associated with a meaningfully reduced risk of cognitive impairment and dementia, adding a compelling longevity angle to drugs already reshaping metabolic medicine. Animal studies reinforce the signal, suggesting these drugs may directly influence brain circuits involved in learning and memory. Important caveat: the data is observational, not causal, and large randomized trials are still needed to confirm whether the brain benefit is real and durable enough to influence prescribing.
Read more →Insomnia and Anxiety Together Sharply Raise Dementia Risk — Far More Than Either Alone
A new analysis finds that older adults who have both insomnia and anxiety face a significantly higher risk of developing Alzheimer's disease and vascular dementia than those managing either condition in isolation — and the effect is synergistic, not simply additive. The two conditions appear to amplify each other's neurological damage in ways that treating only one leaves largely unaddressed. If you're managing sleep or anxiety issues separately, the data makes a strong case for tackling both simultaneously.
Read more →Supplements & Compounds
64% of NMN Supplements Failed Independent Purity Testing — Three Contained None at All
An independent HPLC analysis of 22 top-selling NMN supplements found that 14 of them — 64% — contained less than 1% of their claimed NMN content, and three contained zero NMN whatsoever. The testing was conducted at an ISO-accredited laboratory, making this hard to dismiss. If you're spending money on NMN expecting NAD+ precursor benefits, the odds are not in your favor unless your brand publishes third-party batch test reports.
Read more →Omega-3 Supplements Improve Blood Pressure and Inflammation in Hypertensive Patients
A new analysis finds that omega-3 supplementation delivers meaningful improvements in blood pressure and inflammatory biomarkers in people with hypertension — reinforcing the case for fish oil as more than a general wellness supplement. The findings are especially relevant for those managing cardiovascular risk, where even modest blood pressure reductions translate to significantly better long-term outcomes. Notably, the anti-inflammatory effects appear to operate through mechanisms distinct from blood pressure lowering alone, suggesting dual benefit.
Read more →Folate Does Far More Than Pregnancy: How It Controls Insulin, Inflammation & Blood Vessels
Most people associate folate with prenatal health, but Aviado Research's new analysis shows this B vitamin acts as a biochemical master switch for three critical metabolic pathways. Through one-carbon metabolism, folate supplementation demonstrably lowers fasting insulin, reduces C-reactive protein, and improves vascular flexibility — with meta-analyses showing consistent results across diverse populations. At 400–800 mcg daily, the evidence for cardiovascular and metabolic benefit is strong and the risk profile is low, making it one of the more overlooked foundations in a longevity supplement stack.
Read the full Aviado analysis →Research & Papers
Peter Attia and Huberman Both Stopped Taking Rapamycin — Here's What the Longest Human Study Actually Found
The world's most hyped longevity drug just hit its largest credibility wall. A decade-long analysis of more than 11,000 kidney transplant patients on rapamycin found survival nearly identical to those not taking it — no lifespan extension whatsoever, in humans, over ten years. What makes this particularly significant for the longevity community: Peter Attia and Andrew Huberman have both reportedly stopped taking rapamycin in response to accumulating human data. If you've been considering adding it to your stack, this is essential reading before you do.
Read more →German Scientists Gradually Reversed Human Cell Ages by Decades — Setting a New Benchmark for Rejuvenation
Researchers in Germany used a slow, controlled approach to reverse the biological age of human cells by decades, tracking the de-aging process step by step in a way previous flash-rejuvenation experiments could not. This methodological advance lets scientists observe exactly what changes — and what can go wrong — during cellular rejuvenation, information that prior approaches obscured. Human therapy applications remain distant, but this is the kind of foundational rigor that credible anti-aging medicine is built on.
Read more →Lifestyle & Nutrition
Taking Tirzepatide? A Nature Medicine RCT Proves You Need Resistance Training
A 40-week randomized controlled trial in Nature Medicine assigned 120 adults on tirzepatide to either thrice-weekly resistance training or usual activity — both groups lost about 22 kg, but the composition of that loss was dramatically different. Resistance training preserved 1.09 kg more lean muscle mass and reversed strength declines across all measured muscle groups; tirzepatide alone actually caused strength to fall across bench press, lat pulldown, and knee extension. The trial adherence was 91%, making these results unusually robust. If you're on any GLP-1 or GIP combination therapy, this is the strongest human evidence yet that resistance training isn't optional — it's protective.
Read more →Industry & Policy
Equinox Chair Leads $6.5M Financing Round for Longevity Lab Vesalius
Vesalius Longevity Labs has closed a $6.5 million round led by an investor group organized by Harvey Spevak, chairman of luxury fitness giant Equinox Group — a signal that the fitness industry's most influential players are placing serious bets on longevity science. The investment reflects a broader industry shift toward vertically integrating high-end wellness brands with longevity medicine. When Equinox's chairman writes a check, the category tends to follow.
Read more →